Joaquin Espinoza named associate director of science at the Linda Crnic Institute for Down Syndrome

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JOAQUIN ESPINOZA was named associate director of science at the Linda Crnic Institute for Down Syndrome at the University of Colorado Denver School of Medicine at the Anschutz Medical Campus (CU Anschutz).

His team will continue investigating diverse cancer genes, while also focusing on the remarkable fact that the population with Down syndrome has a much lower risk of developing solid tumors.

Espinosa’s team has moved from the University of Colorado Boulder to the Department of Pharmacology at UCD-SOM in Aurora, where Espinosa will hold a full professorship.

In his new position overseeing science at the Crnic Institute, Espinosa is tasked with expanding beyond the existing Crnic Grand Challenge Grants program that has stimulated 28 labs and nearly 100 scientists to work on Down syndrome research at the University Of Colorado.

He will foster growth in key areas such as Alzheimer’s disease, cancer, autoimmune disorders and clinical research in association with the Sie Center for Down Syndrome at Children’s Hospital Colorado.

He will also work on establishing public-private-university alliances to stimulate research that benefits people with Down syndrome.

Previously Espinosa held the position of associate professor of molecular, cellular and developmental biology at the University of Colorado Boulder, where he will continue as a visiting associate professor.

He will also continue as the University of Colorado’s director of the Functional Genomics Facility and as the co-leader of the Molecular Oncology Program at the University of Colorado Cancer Center.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login